AIDS: The Uses and Limitations of Science

  • June E. Osborn


We are at the mark of an historic anniversary: it was on June 5, 1981, that the Morbidity and Mortality Weekly Reports published a brief summary of five unusual cases of Pneumocystis carinii pneumonia (PCP) occurring in a cluster in previously healthy young men (1). Since PCP had almost always occurred in the context of immune suppression, that clue had been pursued, and indeed their immune systems turned out to be profoundly suppressed. As we now know, that was the faint trumpet that heralded the arrival of a vast pandemic caused by a human retrovirus that had not been recognized before.


Human Immunodeficiency Virus Human Immunodeficiency Virus Type Acquire Immune Deficiency Syndrome Human Immunodeficiency Virus Disease Heterosexual Anal Intercourse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Centers for Disease Control (1981) Pneumocystis pneumonia — Los Angeles. MMWR 30: 250–252Google Scholar
  2. 2.
    Huminer D, Pitlik SD (1988) Further evidence for the existence of AIDS in the pre-AIDS era. Rev Infect Dis 10: 1061PubMedCrossRefGoogle Scholar
  3. 3.
    Temin HM (1989) Is HIV unique or merely different? J Acquir Immune Defic Syndr 2: 1–9PubMedGoogle Scholar
  4. 4.
    Centers for Disease Control (1990) Estimates of HIV prevalence and projected AIDS cases: Summary of a workshop, October 31—November 1, 1989. MMWR 39: 110–119Google Scholar
  5. 5.
    Centers for Disease Control (1981) Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men — New York City and California. MMWR 30: 305–308Google Scholar
  6. 6.
    Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) . Science 220: 868–871PubMedCrossRefGoogle Scholar
  7. 7.
    Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B, White G, Foster P, Markham DP (1984) Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224: 500–503.PubMedCrossRefGoogle Scholar
  8. 8.
    Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM (1984) Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225: 840— 842PubMedCrossRefGoogle Scholar
  9. 9.
    Winkelstein WJ, Samuel M, Padian NS, Wiley JA, Lang W, Anderson RE, Levy JE (1987) The San Francisco men’s health study: III. Reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1982–86. Am J Public Health 76: 685–687 10. Clavel F, Mansinho K, Shamaret S, Gutard D, Favier V, et al (1987) Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl 316: 1180–1185CrossRefGoogle Scholar
  10. 10.
    Clavel F, Mansinho K, Shamaret S, Gutard D, Favier V, et al (1987) Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl 316: 1180–1185CrossRefGoogle Scholar
  11. 11.
    Kiereini E (1990) AIDS in Africa. Plenary presentation at Sixth International AIDS Meeting, San FranciscoGoogle Scholar
  12. 12.
    Marcus R, CDC Cooperative Needlestick Surveillance Group (1988) Surveillance of health care workers exposed to blood from patients infected with the human immunodeficiency virus. N Engl J Med 319: 1118–1123PubMedCrossRefGoogle Scholar
  13. 13.
    Friedland GH, Klein RS (1987) Transmission of the human immunodeficiency virus. N Engl J Med 317: 1125–1135.PubMedCrossRefGoogle Scholar
  14. 14.
    Pape JW, Stanback ME, Pamphile M, Boncy M, Deschamps MH, Verdier R-I, Beaulieu M-E, Blattner W, Liautaud B, Johnson WD (19 90) Prevalence of HIV infection and highrisk activities in Haiti. J Acquir Immune Deficic Syndr 3: 995–1001Google Scholar
  15. 15.
    Müke L (September 1987) Do insects transmit AIDS? (Office of Technology Assessment, Staff Paper 1)Google Scholar
  16. 16.
    Reviewed in: Osborn JE (1988) The AIDS epidemic: Six years. Ann Rev Public Health 9: 551–583CrossRefGoogle Scholar
  17. 17.
    Voeller B (1990) Heterosexual anal intercourse: An AIDS risk factor. In: Voeller B, Reinisch JM, Gottlieb M (eds) AIDS and sex: an integrated biomedical and biobehavioral approach. The Kinsey Institute Series, Oxford University Press, pp 276–310Google Scholar
  18. 18.
    Brandt AM (1988) The syphilis epidemic and its relation to AIDS. Science 239: 375–380PubMedCrossRefGoogle Scholar
  19. 19.
    Rolfs RT, Nakashima AK (1990) Epidemiology of primary and secondary syphilis in the United States, 1981 through 1989.JAMA 264: 1432–1437PubMedCrossRefGoogle Scholar
  20. 20.
    McCune JM (1991) HIV-1: The infective process in vivo. Cell 64: 351–363PubMedCrossRefGoogle Scholar
  21. 21.
    Steffy K, Wong-Staal F (1991) Genetic regulation of human immunodeficiency virus. Microbiol Rev 55: 193–205PubMedGoogle Scholar
  22. 22.
    Lifson AR, Buchbinder SP, Sheppard HW, Mawle AC, Wilber JC, Stanley M, Hart CE, Hessol NA, Holmberg SD (1991) Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: Immunologic and virologic characteristics. J Infect Dis 163: 959–965PubMedCrossRefGoogle Scholar
  23. 23.
    Ho DD, Moudgh T, Alam M (1989) Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Eng J Med 321: 1621–1625CrossRefGoogle Scholar
  24. 24.
    Nowak MA, May RM, Anderson RM (1990) The evolutionary dynamics of HIV-1 quasispecies and the development of immunodeficiency disease. AIDS 4: 1095–1103PubMedCrossRefGoogle Scholar
  25. 25.
    Cloyd MW, Moore BE (1990) Spectrum of biological properties of human immunodeficiency virus (HIV- 1) isolates. Virology 174: 103–116PubMedCrossRefGoogle Scholar
  26. 26.
    Cheng-Mayer C, Quiroga M, Tung JW, Dina D, Levy JA (1990) Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol 64: 4390–4398PubMedGoogle Scholar
  27. 27.
    Centers for Disease Control (1988) Update: Serologic testing for antibody to human immunodeficiency virus. MMWR 36: 833–840Google Scholar
  28. 28.
    Cleary PD, Barry JM, Mayer KH, Brandt AM, Goston L, Fineberg HV (1987) Compulsory premarital screening for the human immunodeficiency virus: Technical and public health considerations. JAMA 258: 1757–1762PubMedCrossRefGoogle Scholar
  29. 29.
    Katzenstein DA, Sawyer LA, Quinnan GV (1988) Issues in the evalution of AIDS vaccines. AIDS 2: 151–155PubMedCrossRefGoogle Scholar
  30. 30.
    Autran B, Plata F, Debre P (1991) MHC-restricted cytotoxicity against HIV. J Acquir Immune Defic Syndr 4: 361–367PubMedGoogle Scholar
  31. 31.
    Palca J (1990) A reliable animal model for AIDS. Science 248: 1078PubMedCrossRefGoogle Scholar
  32. 32.
    Daar ES, Moudgil T, Meyer RD, Ho DD (1991) Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 324: 961–964PubMedCrossRefGoogle Scholar
  33. 33.
    Masur H, Ognibene FP, Yarchoan R, Shelhamer JH, Baird BF, Travis W, Suffredini AF, Deyton L, Kovacs JA, Falloon J, Davey R, Polis M, Metcalf M, Baseler M, Wesley R, Gill VJ, Fauci AS, Lane HC (1989) CD4 counts as predictors of opportunistic pneurnonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 111: 223–231PubMedGoogle Scholar
  34. 34.
    Pulliam L, Herndier BG, Tang NM, McGrath MS (1991) Human imnmunodeficicncy virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains. J Clin Invest 87: 503–512PubMedCrossRefGoogle Scholar
  35. 35.
    Jordan CA, Wakins BA, Kufta C, Dubois-Dalcq M (1991) Infection of brain microglial cells by human immunodeficiency virus type 1 is CD4 dependent. J Virol 65: 736–742PubMedGoogle Scholar
  36. 36.
    Marshall DW, Brey RL, Butzin CA, Lucey DR, Abbadessa SM, Boswell RN (1991) CSF changes in a longitudinal study of 124 neurologically normal HIV-1-infected U.S. Air Force personnel. J Acquir Immune Defic Syndr 4: 777–781PubMedGoogle Scholar
  37. 37.
    Bridge TP, Ingraham JL (1990) Central nervous system effects of human immunodeficiency virus type 1. Ann Rev Med 41: 159–168PubMedCrossRefGoogle Scholar
  38. 38.
    Franzblau A, Letz R, Hershman D, Mason P, Wallace JI, Bekesi JG (1991) Quantitative neurologic and neurobehavioral testing of persons infected with human immunodeficiency virus-1. Arch Neurol (in press)Google Scholar
  39. 39.
    Selnes OA, Miller E, McArthur J, Bordon B, Munoz A, Sheridan K, Fox R, Saah AJ, Multicenter AIDS Cohort Study (1990) HIV-1 infection: No evidence of cognitive decline during the asymptomatic stages. Neurology 40: 204–208PubMedCrossRefGoogle Scholar
  40. 40.
    Miller EN, Selnes OE, McArthur JC, Satz P, Becker JT, Cohen BA, Sheridan K, Machado AM, Van Gorp WG, Visischer B (1990) Neuropsychological performance in HIV-1-infected homosexual men: The Multicenter AIDS Cohort Study (MACS) . Neurology 40: 197–203PubMedCrossRefGoogle Scholar
  41. 41.
    Baltimore D, Feinberg MB (1989) HIV revealed: Toward a natural history of the infection. N Engl J Med 321: 1673–1675PubMedCrossRefGoogle Scholar
  42. 42.
    Saag MS, Crain MJ, Deker WD, Campbell-Hill S, Robinson S, Brown WE, Leuther M, Whitley RJ, Hahn BH, Shaw GM (1991) High-level viremia in adults and children infected with human immunodeficiency virus: Relation to disease stage and CD4+ lymphocyte levels. J Infect Dis 164: 72–80PubMedCrossRefGoogle Scholar
  43. 43.
    Levy JA (1990) Changing concepts in HIV infection: Challenges for the 1990s. AIDS 4: 1051–1058PubMedCrossRefGoogle Scholar
  44. 44.
    Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, Kappes JC, Hahn BH, Shaw GM (1991) High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 324: 954–960PubMedCrossRefGoogle Scholar
  45. 45.
    Tindall B, Cooper DA (1991) Primary AIDS infection: Host responses and intervention strategies. AIDS 5: 1–14PubMedCrossRefGoogle Scholar
  46. 46.
    Biggar RJ, International Registry of Seroconverters (1990) AIDS incubation in 1891 seroconverters from different exposure groups. AIDS 4: 1059–1066PubMedCrossRefGoogle Scholar
  47. 47.
    Jacobson MA, Mills J (1988) Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS) . Ann Intern Med 108: 585–594PubMedGoogle Scholar
  48. 48.
    Gallo R (1991) Kaposi’s sarcoma: A special tumor of AIDS. In: Virus hunting. Basic Books pp 260–275Google Scholar
  49. 49.
    Simpson DM, Bender AN, Farraye J, Mendelson SG, Wolfe DE (1990) Human immunodeficiency virus wasting syndrome may represent a treatable myopathy. Neurology 40: 535–538PubMedCrossRefGoogle Scholar
  50. 50.
    Matsuyama T, Hamamoto Y, Soma CG-I, Mizuno D, Yamamoto N, Kobayashi N (1989) Cytocidal effect of tumor necrosis factor on cells chronically infected with human immnunodeficiency virus (HIV) : Enhancement of HIV replication. J Virol 63: 2504–2509PubMedGoogle Scholar
  51. 51.
    Greenson JK, Belitsos PC, Yardley JH, Bartlett JG (1991)AIDS enteropathy: Occult enteric infections and duodenal mucosal alterations in chronic diarrhea. Ann Intern Med 114: 366–372PubMedGoogle Scholar
  52. 52.
    Navia BA, Cho E-S, Petito CK, Price RW (1986) The AIDS dementia complex: II. Neuropathology. Ann Neurol 19: 525–535Google Scholar
  53. 53.
    Centers for Disease Control (1991) Update: YPLL before age 65 — U.S. 1988 and 1989. MMWR 40: 60–62Google Scholar
  54. 54.
    Richman DD (1991) Antiviral therapy of HIV infection. Ann Rev Med 42: 69–90PubMedCrossRefGoogle Scholar
  55. 55.
    Fischl MA, Parker CB, Pettinelli C, et al (1990) A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 323: 1009–1014PubMedCrossRefGoogle Scholar
  56. 56.
    Moore RD, Hidalgo J, Sugland BW, Chaisson RE (1991) Zidovudine and the natural history of the acquired imunodeficiency syndrome. N Engl J Med 324: 1412–1416PubMedCrossRefGoogle Scholar
  57. 57.
    Fischl MA, Richman DID, Causey DM, Grieco MH, Bryson Y, Mildvan D, Laskin OL, Groopman JE, Volberding PA, Schooley RT, Jackson GG, Durack DT, Andrews JC, Nusinoff-Lehrman S, Barry DW, AZT Collaborative Working Group (1989) Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 262: 2405–2410PubMedCrossRefGoogle Scholar
  58. 58.
    Hirschel B, Lazzarin A, Chopard P, Opravil M, Furrer HJ, Ruttimann S, Vernazza P, Chave JP, Ancarani F, Gabriel V, Heald A, King R, Malinverni R, Martin J-L, Mermillod B, Nicod L, Simoni L, Vivirito MC, Zerboni R, C3-Swiss Group for Clinical Studies on AIDS (1991) A controlled study of inhaled pentamidine for primary prevention of Pneumocystis ccarinii pneumonia. N Engl J Med 324: 1079–1083PubMedCrossRefGoogle Scholar
  59. 59.
    Medina I, Mills J, Leoung G, Hopewell PC, Lee B, Modin G, Benowitz N, Wofsy CB (1990) Oral therapy for Pneumocystis carinii pneumonia in the acquired immnunocieficiency syndrome. N Engl J Med 323: 776–782PubMedCrossRefGoogle Scholar
  60. 60.
    Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS, Murphy RL, Hardy D, Soeiro R, Fischl MA, Bartlett JG, Merigan TC, Hyslop NE, Richman DD, Valentine FT, Coreythe L, AIDS Clinical Trials Group of NIAID (1990) Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 322: 941–949PubMedCrossRefGoogle Scholar
  61. 61.
    Centers for Disease Control (1990) Guidelines for prophylaxis against Pneumocystis carin pneumonia for persons infected with human immunodeficiency virus. MMWR 38: 1–9Google Scholar
  62. 62.
    Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, Knupp C, McLaren C, Pettinelli C, Valentine FT, Dolin R (1990) 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl Med 322: 1333–1340CrossRefGoogle Scholar
  63. 63.
    Hirsch MS (1990) Chemotherapy of human immunodeficiency virus infections: Current practice and future prospects. J Infect Dis 161: 845–857PubMedCrossRefGoogle Scholar
  64. 64.
    Drew WL, Miner RC, Busch DF, Follansbee SE, Gullett J, Mehalko SG, Gordon SM, Owen WF, Matthews TR, Buhles WC, DeArmond B (1991) Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 163: 716–719PubMedCrossRefGoogle Scholar
  65. 65.
    Bozzette SA, Larsen RA, Chiu J, Leal MAE, Jacobsen J, Rothman P, Robinson P, Gilbert G, McCutchan JA, Tilles J, Leedom JM, Richman DD, California Collaborative Treatment Group (1991) A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 324: 580–584PubMedCrossRefGoogle Scholar
  66. 66.
    Masur H (1990) Problems in the management of opportunistic infections in patients infected with human immunodeficiency virus. J Infect Dis 161: 858–864PubMedCrossRefGoogle Scholar
  67. 67.
    Berzofsky JA (1991) Approaches and issues in the development of vaccines against HIV. J Acquir Immune Defic Syndr 4: 451–459PubMedGoogle Scholar
  68. 68.
    Brundage JF, McNeil JG, Miller RN, Gardner LI, Harrison SM, Hawks C, Craig DB, Redfield R, Burke DS, U.S. Army Retrovirus Research Group (1990) The current distribution of CD4+ T-lymphocyte counts among adults in the United States with human immunodeficiency virus infections: Estimates based on the experience of the U.S. Army. J Acquir Immune Defic Syndr 3: 92–94PubMedGoogle Scholar
  69. 69.
    Gwinn M, Pappaioanou M, George JR, Hannon WH, Wasser SC, Redus MA, Hoff R, Grady GF, Willoughby A, Novello AC, Petersen LR, Dondero TJ, Curran JW (1991) Prevalence of HIV infection in childbearing women in the United States. JAMA 265: 1704–1708PubMedCrossRefGoogle Scholar
  70. 70.
    Verghese A, Berk SL, Sarubbi F (1989) Urbs in rure: Human immunodeficiency virus infection in rural Tennessee. J Infect Dis 160: 1051–1055PubMedCrossRefGoogle Scholar
  71. 71.
    U.S. Public Health Service (1991) Healthy People 2000. National Health Promotion and Disease Prevention Objectives. Washington, D.C., DHHS Publication No (PHS) 91–50213Google Scholar
  72. 72.
    Hingson R, Strunin L, Berlin B (1990) Acquired immunodeficiency syndrome transmission: Changes in knowledge and behaviors among teenagers, Massachusetts statewide surveys, 1986 to 1988. Pediatr 85: 24–29Google Scholar
  73. 73.
    Turner CF, Miller HG, Moses LE (eds) (1989) Facilitating change in health behaviors. In: AIDS. Sexual Behavior and Intravenous Drug Use. Washington, National Academy Press, pp 259–315Google Scholar
  74. 74.
    Osborn JE (1990) AIDS: Challenges to our health care systems. Cleve Clin J Med 57: 709— 714PubMedGoogle Scholar
  75. 75.
    Van de Perre P, Jacobs D, Sprecher-Goldberger S (1987) The latex condom, an efficient barrier against sexual transmission of AIDS-related viruses. AIDS 1: 49–52PubMedGoogle Scholar
  76. 76.
    Des Jarlais DC, Friedman SR (1989) AIDS and IV drug use. Science 245: 578PubMedCrossRefGoogle Scholar
  77. 77.
    Stryker J (1989) IV drug use and AIDS: Public policy and dirty needles. J Health Polit Policy Law 14: 719–740PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • June E. Osborn
    • 1
  1. 1.University of Michigan School of Public Health and National Commission on AIDSUSA

Personalised recommendations